Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553742303> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2553742303 abstract "Abstract Therapy with ATP-competitive ABL kinase inhibitors, including imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna), has revolutionized the treatment of chronic myeloid leukemia (CML), but a substantial proportion of patients develop resistance to these agents. A major mechanism of acquired resistance is mutations in the ABL kinase domain that render BCR-ABL insensitive to the drug; in particular, mutation of the ABL kinase “gatekeeper” Thr315 residue to Ile (T315I) confers pan-resistance to all ATP-competitive ABL inhibitors. To address this need, we developed and characterized a novel chemical class of compounds that bind to five structural pockets involved in the endogenous “switch” mechanism used by the ABL kinase to conformationally control its activity state. Using a structure-based drug design approach, diversity in these “switch pockets” between kinases can be exploited to develop inhibitors with high potency and specificity. The resulting ABL inhibitors have several attractive features, as they: act through a non-ATP-competitive mechanism; avoid steric clash with Ile315; inhibit purified ABL that is either unphosphorylated (switch-off) or phosphorylated (switch-on) at Tyr393 with IC50 of 0.8–4.0 nM; co-crystallize with phospho-Y393-ABL WT and T315I; and have very prolonged residency time on the kinase (off-rate ∼400 min vs. 3 min for imatinib). A lead compound, DCC-2036, is highly selective for ABL, FLT3, and SRC family kinases, and has favorable pharmacokinetic and toxicity profiles in animals. In vitro, DCC-2036 inhibited proliferation and induced apoptosis of Ba/F3 cells expressing BCR-ABL WT or several common imatinib-resistant mutants (Y253F, T315I, M351T) with IC50 from 5 to 25 nM, without appreciable inhibition of parental Ba/F3 cells in IL-3 (IC50 >1000 nM). In Balb/c mice injected with Ba/F3-BCR-ABL T315I cells, pharmacodynamic studies indicated >8 hour inhibition of phospho-Stat5 and phospho-ABL in the leukemic cells following a single oral 100 mg/kg dose of DCC-2036, whereas daily dosing of DCC-2036 significantly prolonged survival. In the mouse retroviral bone marrow transduction/transplantation model of CML, DCC-2036 at 100 mg/kg/d also reduced peripheral blood leukocyte counts and significantly prolonged survival vs. vehicle-treated control mice. These results demonstrate that ABL switch pocket inhibitors are a promising new pharmacologic weapon for the treatment of de novo and drug-resistant CML, including BCR-ABL T315I." @default.
- W2553742303 created "2016-11-30" @default.
- W2553742303 creator A5015316325 @default.
- W2553742303 creator A5021581834 @default.
- W2553742303 creator A5023743448 @default.
- W2553742303 creator A5030901865 @default.
- W2553742303 creator A5057286638 @default.
- W2553742303 creator A5058762709 @default.
- W2553742303 creator A5070184560 @default.
- W2553742303 creator A5073524555 @default.
- W2553742303 creator A5082758903 @default.
- W2553742303 creator A5084297083 @default.
- W2553742303 date "2007-11-16" @default.
- W2553742303 modified "2023-10-01" @default.
- W2553742303 title "DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model." @default.
- W2553742303 doi "https://doi.org/10.1182/blood.v110.11.463.463" @default.
- W2553742303 hasPublicationYear "2007" @default.
- W2553742303 type Work @default.
- W2553742303 sameAs 2553742303 @default.
- W2553742303 citedByCount "14" @default.
- W2553742303 crossrefType "journal-article" @default.
- W2553742303 hasAuthorship W2553742303A5015316325 @default.
- W2553742303 hasAuthorship W2553742303A5021581834 @default.
- W2553742303 hasAuthorship W2553742303A5023743448 @default.
- W2553742303 hasAuthorship W2553742303A5030901865 @default.
- W2553742303 hasAuthorship W2553742303A5057286638 @default.
- W2553742303 hasAuthorship W2553742303A5058762709 @default.
- W2553742303 hasAuthorship W2553742303A5070184560 @default.
- W2553742303 hasAuthorship W2553742303A5073524555 @default.
- W2553742303 hasAuthorship W2553742303A5082758903 @default.
- W2553742303 hasAuthorship W2553742303A5084297083 @default.
- W2553742303 hasConcept C104317684 @default.
- W2553742303 hasConcept C125418893 @default.
- W2553742303 hasConcept C143065580 @default.
- W2553742303 hasConcept C150109051 @default.
- W2553742303 hasConcept C184235292 @default.
- W2553742303 hasConcept C185592680 @default.
- W2553742303 hasConcept C2777413986 @default.
- W2553742303 hasConcept C2777583451 @default.
- W2553742303 hasConcept C2778729363 @default.
- W2553742303 hasConcept C2779536868 @default.
- W2553742303 hasConcept C3019892230 @default.
- W2553742303 hasConcept C32619005 @default.
- W2553742303 hasConcept C42362537 @default.
- W2553742303 hasConcept C502942594 @default.
- W2553742303 hasConcept C55493867 @default.
- W2553742303 hasConcept C62478195 @default.
- W2553742303 hasConcept C86803240 @default.
- W2553742303 hasConcept C97029542 @default.
- W2553742303 hasConcept C98274493 @default.
- W2553742303 hasConceptScore W2553742303C104317684 @default.
- W2553742303 hasConceptScore W2553742303C125418893 @default.
- W2553742303 hasConceptScore W2553742303C143065580 @default.
- W2553742303 hasConceptScore W2553742303C150109051 @default.
- W2553742303 hasConceptScore W2553742303C184235292 @default.
- W2553742303 hasConceptScore W2553742303C185592680 @default.
- W2553742303 hasConceptScore W2553742303C2777413986 @default.
- W2553742303 hasConceptScore W2553742303C2777583451 @default.
- W2553742303 hasConceptScore W2553742303C2778729363 @default.
- W2553742303 hasConceptScore W2553742303C2779536868 @default.
- W2553742303 hasConceptScore W2553742303C3019892230 @default.
- W2553742303 hasConceptScore W2553742303C32619005 @default.
- W2553742303 hasConceptScore W2553742303C42362537 @default.
- W2553742303 hasConceptScore W2553742303C502942594 @default.
- W2553742303 hasConceptScore W2553742303C55493867 @default.
- W2553742303 hasConceptScore W2553742303C62478195 @default.
- W2553742303 hasConceptScore W2553742303C86803240 @default.
- W2553742303 hasConceptScore W2553742303C97029542 @default.
- W2553742303 hasConceptScore W2553742303C98274493 @default.
- W2553742303 hasLocation W25537423031 @default.
- W2553742303 hasOpenAccess W2553742303 @default.
- W2553742303 hasPrimaryLocation W25537423031 @default.
- W2553742303 hasRelatedWork W1963576043 @default.
- W2553742303 hasRelatedWork W2042520753 @default.
- W2553742303 hasRelatedWork W2064109729 @default.
- W2553742303 hasRelatedWork W2122367401 @default.
- W2553742303 hasRelatedWork W2534851254 @default.
- W2553742303 hasRelatedWork W2551370723 @default.
- W2553742303 hasRelatedWork W2553742303 @default.
- W2553742303 hasRelatedWork W2559877690 @default.
- W2553742303 hasRelatedWork W2565152163 @default.
- W2553742303 hasRelatedWork W2979571032 @default.
- W2553742303 isParatext "false" @default.
- W2553742303 isRetracted "false" @default.
- W2553742303 magId "2553742303" @default.
- W2553742303 workType "article" @default.